Overview  Patient Data  Geographic Referral Patterns  Links

The mission of the Duke Tumor Registry is to contribute to the knowledge of cancer prevention, diagnosis and treatment and to contribute to improvements in cancer patient management through the collection of complete, accurate and timely cancer data and by ongoing follow-up of patients.  The registry provides cancer incidence, treatment, and outcome information and trend data for administrative planning and marketing, development of support programs, quality improvement and research activities.  Data are submitted to the North Carolina Central Cancer Registry in compliance with state reporting requirements to support statewide improvements in cancer detection and treatment.

Our primary customers are:
•    Administrators/Directors (Planning & Development of New Programs)
•    Center for Cancer Survivorship (Survivor Events, Education Events, Support Programs)
•    Researchers (Case Finding for New Studies; Follow Up for ongoing studies)
•    North Carolina Central Cancer Registry (State-mandated reporting)
•    Outside Registries (Request Diagnostic, Treatment, Follow Up Information)

Duke Tumor Registry Staff

Eileen J. Morgan, MPA, CTR Director, Duke an Durham Regional Tumor Registry	919-684-0330
Iris A. Katz, BA, CTR Data Specialist	919-257-9487 Data & Research Requests
Shelley S. Alvey	Tumor Registrar
Deborah A. Belvin	Tumor Registrar
Debra J. Carroll, CTR	Tumor Registrar
Michelle N. Chatman, AA	Tumor Registrar
Rhonda L. Hamblin, AA, RHIT	Tumor Registrar
Sathya N. Kasala, BS, CTR	Tumor Registrar
Deborah L. Mangum, BSW	Tumor Registrar

 
Primary Site Distribution for All Cases 1st Seen at Duke in 2008       

A total of 5678 cases (including non-malignant CNS tumors) diagnosed and/or treated at Duke Hospital or in the Duke Physician Diagnostic Clinics (PDC) were added to the registry database for the year 2008.  Close to 83% are analytic cases (newly diagnosed); 55% of the analytic cases were diagnosed elsewhere and referred to Duke for all or part of their initial treatment.  Non-analytic patients (about 17% of all cases) come to Duke for treatment after initial treatment failure or with recurrent disease.

The most common cases seen in 2008 were:  Digestive, Brain & CNS, Male Genital, Breast, Respiratory and Female Genital cancers.



2008 Analytic Case Profile       

Analytic cases (n=4713) are patients either initially diagnosed at Duke or newly diagnosed elsewhere who are referred to Duke for all or part of their initial treatment.  Fifty-four (55%) percent of the analytic cases were referrals to Duke for treatment.  Of the 4713 analytic cases, 52% are male (n=2463) and 48% are female (n=2250).

The most common types of analytic cases are Digestive, Brain & CNS, Male Genital, Respiratory and Breast cancers.

Note:  patients who come to Duke only for a 2nd opinion consult are not entered into the registry database.



2008 Non-Analytic Case Profile       

Non-analytic cases (n=965) were diagnosed elsewhere and received all of their initial treatment prior to coming to Duke.

Treatment at Duke is either for initial treatment failure (progression of disease) or recurrent disease.  Non-analytic cases also include cases diagnosed at autopsy.    Of the 965 non-analytic cases, 51% are male (n=494) and 49% are female (n=471).

The most common non-analytic cases are Brain & CNS tumors (n=204), a reflection of the wide referral network developed by the Brain Tumor Center at Duke.  The next most common non-analytic cases are Digestive, Breast, Lymphoma, Male Genital and Respiratory cancers.



All 2008 Cases By Primary Site

 

Table 1  Duke University Hospital--Cases 1st Seen in 2008
	Class of Case			Percent
Primary Site	Analytic	Non-Analytic	Total	of Total
LIP	1	0	1	0.0
TONGUE	36	5	41	0.7
SALIVARY GLANDS	10	0	10	0.2
FLOOR OF MOUTH	6	1	7	0.1
GUM & OTHER MOUTH	17	2	19	0.3
NASOPHARYNX	3	0	3	0.1
TONSIL	19	1	20	0.4
OROPHARYNX	4	0	4	0.1
HYPOPHARYNX	5	0	5	0.1
OTHER ORAL CAVITY & PHARYNX	2	2	4	0.1
TOTAL Oral & Pharynx	103	11	114	2.0
ESOPHAGUS	63	4	67	1.2
STOMACH	49	7	56	1.0
SMALL INTESTINE	20	2	22	0.4
CECUM	26	12	38	0.7
APPENDIX	7	1	8	0.1
ASCENDING COLON	22	7	29	0.5
HEPATIC FLEXURE	5	1	6	0.1
TRANSVERSE COLON	13	5	18	0.3
SPLENIC FLEXURE	2	1	3	0.1
DESCENDING COLON	8	8	16	0.3
SIGMOID COLON	28	26	54	1.0
LARGE INTESTINE, NOS	3	21	24	0.4
Total COLON, EXCL RECTUM	114	82	196	3.5
RECTOSIGMOID JUNCTION	6	9	15	0.3
RECTUM	78	25	103	1.8
Total RECTUM & RECTOSIGMOID	84	34	118	2.1
ANUS,ANAL CANAL,ANORECTUM	20	1	21	0.4
LIVER	90	3	93	1.6
INTRAHEPATIC BILE DUCT	12	0	12	0.2
Total LIVER & INTRAHEPATIC BILE DUCT	102	3	105	1.8
GALLBLADDER	11	0	11	0.2
OTHER BILIARY	32	0	32	0.6
PANCREAS	172	5	177	3.1
RETROPERITONEUM	4	2	6	0.1
PERITONEUM,OMENTUM,MESENTERY	9	2	11	0.2
OTHER DIGESTIVE ORGANS	3	0	3	0.1
TOTAL Digestive System	683	142	825	14.5

 

 

Table 1  Duke University Hospital--Cases 1st Seen in 2008  (cont.)
	Class of Case			Percent
Primary Site	Analytic	Non-Analytic	Total	of Total
NOSE,NASAL CAV & MIDDLE EAR	10	1	11	0.2
LARYNX	32	2	34	0.6
LUNG & BRONCHUS	544	69	613	10.8
PLEURA	0	0	0	0.0
TRACHEA, MEDIASTINUM & HEART	4	0	4	0.1
TOTAL Respiratory System	590	72	662	11.7
TOTAL Bones & Joints	17	4	21	0.4
TOTAL Soft Tissue	80	8	88	1.5
MELANOMAS -- SKIN	238	42	280	4.9
OTHER NON-EPITHELIAL SKIN	12	7	19	0.3
TOTAL Skin	250	49	299	5.3
TOTAL Breast	525	114	639	11.3
CERVIX UTERI	29	1	30	0.5
CORPUS UTERI	147	5	152	2.7
UTERUS, NOS	3	1	4	0.1
OVARY	105	14	119	2.1
VAGINA	6	0	6	0.1
VULVA	30	0	30	0.5
OTHER FEMALE GENITAL ORGANS	5	1	6	0.1
TOTAL Female Genital System	325	22	347	6.1
PROSTATE	536	72	608	10.7
TESTIS	25	3	28	0.5
PENIS	5	1	6	0.1
OTHER MALE GENITAL ORGANS	1	0	1	0.0
TOTAL Male Genital System	567	76	643	11.3
URINARY BLADDER	92	18	110	1.9
KIDNEY & RENAL PELVIS	137	20	157	2.8
URETER	5	2	7	0.1
OTHER URINARY ORGANS	4	0	4	0.1
TOTAL Urinary System	238	40	278	4.9
TOTAL Eye & Orbit	58	1	59	1.0
BRAIN	448	179	627	11.0
CRANIAL NERVES & OTHER NERVES	172	25	197	3.5
TOTAL Brain & Other Nervous System	620	204	824	14.5
THYROID	83	13	96	1.7
OTHER ENDOCRINE INCL THYMUS	53	10	63	1.1
TOTAL Endocrine System	136	23	159	2.8

 

Table 1  Duke University Hospital--Cases 1st Seen in 2008  (cont.)
	Class of Case			Percent
Primary Site	Analytic	Non-Analytic	Total	of Total
HODGKIN-NODAL DISEASE	25	12	37	0.7
HODGKIN-EXTRANODAL DISEASE	0	0	0	0.0
Total HODGKIN'S DISEASE	25	12	37	0.7
NODAL NHL	104	56	160	2.8
EXTRANODAL NHL	82	20	102	1.8
Total NHL	186	76	262	4.6
TOTAL Lymphomas	211	88	299	5.3
TOTAL Myeloma	69	25	94	1.7
ACUTE LYMPHOCYTIC	27	12	39	0.7
CHRONIC LYMPHOCYTIC	21	18	39	0.7
OTHER LYMPHOCYTIC	1	1	2	0.0
Total LYMPHOCYTIC Leukemia	49	31	80	1.4
ACUTE MYELOID	60	15	75	1.3
ACUTE MONOCYTIC	10	2	12	0.2
CHRONIC MYELOID	8	6	14	0.2
OTHER MYELOID/MONOCYTIC	3	0	3	0.1
Total MYELOID & MONOCYTIC Leukemia	81	23	104	1.8
OTHER ACUTE LEUKEMIA	2	3	5	0.1
ALEUKEMIC, SUBLEUKEMIC	4	0	4	0.1
Total OTHER Leukemia	6	3	9	0.2
TOTAL Leukemias	136	57	193	3.4
TOTAL Mesothelioma	17	1	18	0.3
TOTAL Kaposi Sarcoma	1	0	1	0.0
TOTAL Ill-Defined & Unknown Primary	87	28	115	2.0
GRAND TOTAL	4713	965	5678	100.0

Geographic Referral Patterns

State/County Residence of All patients first seen at Duke in 2008:
Overall, 73% of the patients first seen at Duke in 2008 reside in North Carolina.  The top six counties of residence were:  Durham, Wake, Orange, Cumberland, Granville and Guilford counties.  Of the patients who reside outside North Carolina (25%), the top six states were:  Virginia, South Carolina, Florida Georgia, Tennessee and West Virginia.

View a map showing which counties in North Carolina patients came from in 2008

View a map showing which states and countries patients came from in 2008

To make the maps larger, you can zoom in by either right clicking the mouse or by using the toolbar above the map.

State/County Residence of Analytic patients first seen at Duke in 2008:
Seventy-nine percent (77%) of the Analytic patients (newly diagnosed) reside in North Carolina.  The top six counties of residence were:  Durham, Wake, Orange, Cumberland, Granville and Alamance counties.  Of the patients who reside outside North Carolina (23%), the top six states were:  Virginia, South Carolina, Florida Georgia, Tennessee and West Virginia.

State/County Residence of Non-analytic patients first seen at Duke in 2008:
North Carolina residents represent only 58% of the non-analytic patients who come to Duke for treatment of progression or recurrent disease.  This is a significant difference from analytic patients, 77% of whom come from North Carolina.  For non-analytic patients the top six counties of residence were:  Wake, Durham, Guilford, Mecklenburg, Cumberland and Granville counties.  Of the patients who reside outside North Carolina, the top six states were:  Virginia, South Carolina, Florida, Georgia, Tennessee and West Virginia.


Glossary

Analytic case:
Cancer/tumor either initially diagnosed at Duke or newly diagnosed elsewhere and referred to Duke for all or part of their initial treatment

Non-Analytic case:   
Cancer/tumor diagnosed elsewhere and received all initial treatment prior to coming to Duke.  Treatment at Duke is either for initial treatment failure (progression of disease) or recurrent disease.  Non-analytic cases also include cases diagnosed at autopsy.


References
Cancer Statistics, 2008 (CA-A Cancer Journal for Clinicians, 2008; 58:71-96)

Commission on Cancer, Cancer Program Standards 2004.  American College of Surgeons, Chicago, IL.

International Classification of Diseases for Oncology, 3rd Edition, World Health Organization, 2001.

AJCC Cancer Staging Manual, 6th Edition, American Joint Committee on Cancer, New York, NY:  Springer-Verlag, 2002.


Cancer Statistics - Links

American Cancer Society – CA-A Cancer Journal for Clinicians (on-line)
(Cancer Statistics in January/February or March/April issue each year)

Commission on Cancer of the American College of Surgeons

International Association of Cancer Registries

National Cancer Data Base

NCI – State Cancer Profiles

NCI – SEER (Surveillance Epidemiology and End Results)

North American Association of Central Cancer Registries (NAACCR)

North Carolina Central Cancer Registry